The first patient has enrolled in a clinical trial evaluating both the efficacy and safety of diacerein 1% ointment (CCP-020) in treating epidermolysis bullosa simplex (EBS), Castle Creek Pharmaceuticals recently announced. The company’s Phase 2/3 DELIVERS clinical trial (NCT03154333) is currently recruiting participants. CCP-020 is a small molecule, engineered to…
News
News
FDA Grants Rare Pediatric Disease Designation to EB-101 as a Treatment for Blistering Skin Disorder
The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101,  Abeona Therapeutics’ treatment for the inherited skin disease epidermolysis bullosa, or EB. Importantly, the designation also covers a severe form of the blistering and open-wound disorder known as recessive dystrophic epidermolysis bullosa, or RDEB. The FDA…
Recent Posts
- Why hobbies are important in life with epidermolysis bullosa
- FDA fast track status aiming to speed TolaSure Gel to fragile skin patients
- Health Canada grants priority review to Filsuvez for EB wound care
- 17 years later, I’m still learning how to navigate EB — and parenthood
- People with RDEB note disease impact, but report better life quality with age